Sanofi mRNA vaccine trial ends early – what we know
NCT ID NCT04798027
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested Sanofi's experimental mRNA vaccine against COVID-19 in 182 healthy adults aged 18 and older. The main goals were to check safety and measure the body's immune response. The trial was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SARS-CoV-2 mRNA vaccine
- What this could lead to
- If successful, this could lead to a new mRNA vaccine option for COVID-19.
- What could go wrong
- This was an early (Phase 1/2) trial that was terminated, so results are limited. It is unclear if the vaccine would have been effective or safe in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site Number :0360001
Melbourne, Victoria, 3010, Australia
-
Investigational Site Number :0360002
Nedlands, Western Australia, 6009, Australia
-
Investigational Site Number :0360003
Morayfield, Queensland, 4506, Australia
-
Investigational Site Number :0360005
South Brisbane, Queensland, 4101, Australia
-
Investigational Site Number :0760001
Salvador, Estado de Bahia, 40415-006, Brazil
-
Investigational Site Number :0760003
Belo Horizonte, Minas Gerais, 30110-063, Brazil
-
Investigational Site Number :0760004
Campo Grande, Mato Grosso do Sul, 79070-900, Brazil
-
Investigational Site Number :3400001
San Pedro Sula, 21104, Honduras
-
Investigational Site Number :3400002
Barrio del Centro, 11101, Honduras
-
Investigational Site Number :8400001
Rochester, New York, 14609, United States
-
Investigational Site Number :8400002
Hollywood, Florida, 33024, United States
-
Investigational Site Number :8400003
Rolling Hills Estates, California, 90274, United States
-
Investigational Site Number :8400004
North Charleston, South Carolina, 29405, United States
-
Investigational Site Number :8400005
Salt Lake City, Utah, 84107, United States
-
Investigational Site Number :8400006
Miami, Florida, 33135, United States
-
Investigational Site Number :8400007
Kansas City, Missouri, 64114, United States
-
Investigational Site Number :8400008
Omaha, Nebraska, 68134, United States
-
Investigational Site Number :8400009
Houston, Texas, 77081, United States
-
Investigational Site Number :8400010
Philadelphia, Pennsylvania, 19104, United States
-
Investigational Site Number :8400015
Knoxville, Tennessee, 37920, United States
-
Investigational Site Number :8400017
Iowa City, Iowa, 52242, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?